
<DOC>
<DOCNO>
WSJ900924-0139
</DOCNO>
<DOCID>
900924-0139.
</DOCID>
<HL>
   Upjohn Sells Rights
   To Brands to Roberts
   Pharmaceutical Corp.
</HL>
<DATE>
09/24/90
</DATE>
<SO>
WALL STREET JOURNAL (J), PAGE B13B
</SO>
<CO>
   RPCX UPJ
</CO>
<IN>
TENDER OFFERS, MERGERS, ACQUISITIONS (TNM)
DRUG MANUFACTURERS (DRG)
</IN>
<LP>
   EATONTOWN, N.J. -- Roberts Pharmaceutical Corp. said it
purchased the rights to several brands in the U.S., Canada,
Britain and Ireland from Upjohn Co., a health care company
based in Kalamazoo, Mich. Terms weren't disclosed.
   Roberts, which acquires, develops and markets
pharmaceuticals, acquired several respiratory and analgesic
brands, including Cheracol and Orthoxicol cough syrups,
Pyrroxate cold and allergy medicine, P-A-C aspirin tablets,
and Haltran, an ibuprofen product.
</LP>
<TEXT>
   It also purchased other nutritional brands such as the
multivitamin supplements Zymacap, Sigtab and Super D Perles;
the calcium supplements Calcium Lactate tablets and Calcium
Gluconate tablets; the dietary supplement Diostsate D; and
Lipomul, a product that increases calorie intake. Roberts
also bought the brand Clocream, a hand cream.
   For the nine months ended March 31, Roberts, which went
public last January, had a net loss of $3.3 million, or 65
cents a share, on sales of $972,500.
   In national over-the-counter trading Friday, Roberts
shares closed at $3.75, up 25 cents.
</TEXT>
</DOC>